Latest Breaking News On - Eurocine vaccine - Page 1 : comparemela.com
Outstanding results for Eurocine Vaccines mRNA based HSV-2 candidate
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Positive results with Endocine™ and a vaccine candidate against COVID-19
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Positive results with Endocine™ and a vaccine candidate against COVID-19
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Eurocine Vaccines Adjuvant Technology Endocine is evaluated with a vaccine candidate against COVID-19
Eurocine Vaccines has signed a Material Transfer Agreement regarding the evaluation of Endocine together with a vaccine candidate against COVID-19
STOCKHOLM, May 19, 2021 /PRNewswire/ Eurocine Vaccines has signed an evaluation agreement, a Material Transfer Agreement, with an innovative, North American, small public company, regarding the evaluation of Endocine together with a vaccine candidate against COVID-19. Studies in one or two animal species will be conducted to study both potency and safety.
Endocine is Eurocine Vaccines proprietary adjuvant platform based on natural lipid compounds and formulated as a liposomal dispersion. The manufacture of bulk adjuvant has been established in pilot-scale at GMP conditions and shown excellent safety and tolerability in more than 400 human subjects after nasal administration in five clinical trials.
Share this article
Share this article
STOCKHOLM, May 19, 2021 /PRNewswire/ Eurocine Vaccines has signed an evaluation agreement, a Material Transfer Agreement, with an innovative, North American, small public company, regarding the evaluation of Endocine™ together with a vaccine candidate against COVID-19. Studies in one or two animal species will be conducted to study both potency and safety.
Endocine™ is Eurocine Vaccines proprietary adjuvant platform based on natural lipid compounds and formulated as a liposomal dispersion. The manufacture of bulk adjuvant has been established in pilot-scale at GMP conditions and shown excellent safety and tolerability in more than 400 human subjects after nasal administration in five clinical trials.